Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation.

Bassiouny M, Saliba W, Rickard J, Shao M, Sey A, Diab M, Martin DO, Hussein A, Khoury M, Abi-Saleh B, Alam S, Sengupta J, Borek PP, Baranowski B, Niebauer M, Callahan T, Varma N, Chung M, Tchou PJ, Kanj M, Dresing T, Lindsay BD, Wazni O.

Circ Arrhythm Electrophysiol. 2013 Jun;6(3):460-6. doi: 10.1161/CIRCEP.113.000320. Epub 2013 Apr 3. Erratum in: Circ Arrhythm Electrophysiol. 2013 Oct;6(5):e79.

2.

Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.

Bin Abdulhak AA, Khan AR, Tleyjeh IM, Spertus JA, Sanders SU, Steigerwalt KE, Garbati MA, Bahmaid RA, Wimmer AP.

Europace. 2013 Oct;15(10):1412-20. doi: 10.1093/europace/eut239. Epub 2013 Aug 16. Review.

PMID:
23954918
3.

Safety and efficacy of dabigatran compared with warfarin for patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis.

Shurrab M, Morillo CA, Schulman S, Kansal N, Danon A, Newman D, Lashevsky I, Healey JS, Crystal E.

Can J Cardiol. 2013 Oct;29(10):1203-10. doi: 10.1016/j.cjca.2013.07.005. Epub 2013 Aug 29. Review.

PMID:
23993352
4.

Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis.

Providência R, Albenque JP, Combes S, Bouzeman A, Casteigt B, Combes N, Narayanan K, Marijon E, Boveda S.

Heart. 2014 Feb;100(4):324-35. doi: 10.1136/heartjnl-2013-304386. Epub 2013 Jul 22. Review.

5.

Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.

Alonso-Coello P, Zhou Q, Guyatt G.

Thromb Haemost. 2012 Oct;108(4):647-53. Epub 2012 Aug 23. Review.

PMID:
22918481
6.

Meta-analysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation.

Sardar P, Nairooz R, Chatterjee S, Wetterslev J, Ghosh J, Aronow WS.

Am J Cardiol. 2014 Apr 1;113(7):1173-7. doi: 10.1016/j.amjcard.2013.12.027. Epub 2014 Jan 15. Review.

PMID:
24513472
7.

Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature.

Hohnloser SH, Camm AJ.

Europace. 2013 Oct;15(10):1407-11. doi: 10.1093/europace/eut241. Epub 2013 Aug 16. Review.

PMID:
23954917
8.

Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.

Aryal MR, Ukaigwe A, Pandit A, Karmacharya P, Pradhan R, Mainali NR, Pathak R, Jalota L, Bhandari Y, Donato A.

Am J Cardiol. 2014 Aug 15;114(4):577-82. doi: 10.1016/j.amjcard.2014.05.038. Epub 2014 Jun 6. Review.

PMID:
24998087
9.

Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide.

Hesselbjerg LJ, Pedersen HS, Asmussen MB, Petersen KD.

J Med Econ. 2013 Jul;16(7):845-58. doi: 10.3111/13696998.2013.800523. Epub 2013 May 15. Review.

10.

[Atrial fibrillation: novel possibilities of anticoagulant therapy in patients subjected to cardioversion].

Averkov OV.

Kardiologiia. 2011;51(7):53-7. Review. Russian. No abstract available.

PMID:
21878086
11.

Meta-analysis of dabigatran vs warfarin in patients undergoing catheter ablation for atrial fibrillation.

Phan K, Wang N, Pison L, Kumar N, Hitos K, Thomas SP.

Int J Cardiol. 2015 Jun 15;189:199-203. doi: 10.1016/j.ijcard.2015.04.072. Epub 2015 Apr 11. Review. No abstract available.

PMID:
25897906
12.

[Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].

Panchenko EP.

Kardiologiia. 2011;51(11):83-90. Review. Russian. No abstract available.

PMID:
22117775
13.

Apixaban for periprocedural anticoagulation during catheter ablation of atrial fibrillation: a systematic review and meta-analysis of 1691 patients.

Blandino A, Bianchi F, Biondi-Zoccai G, Grossi S, Conte MR, Rametta F, Gaita F.

J Interv Card Electrophysiol. 2016 Sep;46(3):225-36. doi: 10.1007/s10840-016-0141-6. Epub 2016 May 23. Review.

PMID:
27217030
14.

Thromboembolic and bleeding risks in patients undergoing atrial fibrillation ablation: oral anticoagulation perspectives.

Briceño DF, Madan N, Romero J, Londoño A, Villablanca PA, Natale A, Di Biase L.

Expert Opin Drug Saf. 2017 Jul;16(7):769-777. doi: 10.1080/14740338.2017.1325867. Epub 2017 Jun 15. Review.

PMID:
28475380
15.

Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation.

Vazquez SR, Johnson SA, Rondina MT.

Thromb Res. 2010 Aug;126(2):e69-77. doi: 10.1016/j.thromres.2009.11.031. Epub 2010 Jan 6. Review.

16.
17.

[Specifics for anticoagulation with atrial fibrillation: triple therapy and perioperative bridging].

Frantz S.

Dtsch Med Wochenschr. 2016 Oct;141(22):1624-1627. Epub 2016 Nov 4. Review. German.

PMID:
27824418
18.

Perioperative Management of Anticoagulation-Review of Latest Evidence.

Kannan A, Poongkunran C, Shenoy S, Abidov A.

Am J Ther. 2016 Mar-Apr;23(2):e474-84. doi: 10.1097/MJT.0000000000000121. Review.

PMID:
26214205
19.

Atrial fibrillation in the elderly: anticoagulation strategies and indications in the very elderly.

Kamath S, Lip GY.

Am J Geriatr Cardiol. 2002 Nov-Dec;11(6):357-62; quiz 363-4. Review.

PMID:
12417841
20.

Risk stratification, perioperative and periprocedural management of the patient receiving anticoagulant therapy.

Oprea AD, Noto CJ, Halaszynski TM.

J Clin Anesth. 2016 Nov;34:586-99. doi: 10.1016/j.jclinane.2016.06.016. Epub 2016 Jul 18. Review.

PMID:
27687455

Supplemental Content

Support Center